Insmed Incorporated's treprostinil palmitil inhalation powder (TPIP) demonstrated 35% pulmonary vascular resistance reduction and 35.5 metre 6-minute walking distance (6MWD) improvement in its Phase IIb pulmonary arterial hypertension (PAH) trial, triggering a 29% stock rise (USD 16.6 billion market cap).

The once-daily therapy showed superior tolerability (85% mild cough) versus current prostacyclin analogues requiring 4x daily dosing. The 102-patient study also reported 60% reduction in cardiac stress marker NT-proBNP and 15% cardiac index increase.

TPIP's success follows Merck's sotatercept (USD 419 million 2024 sales), potentially advancing prostacyclin therapy efficacy.

Source:
https://mp.weixin.qq.com/s?__biz=MzI4MzQyMjM0Ng==&mid=2247527515&idx=1&sn=f741d7498655eee90fd88fd3a86e83e9